KUALA LUMPUR, Jan 19 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder.
In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations, according to a statement.
“We’re incredibly excited that Choi-Rivera is joining AGC Biologics as the General Manager at our Boulder facility. She brings tremendous experience in both GMP manufacturing and project management,” said AGC Biologics Executive Vice President of U.S. Operations, J.D. Mowery.
Choi-Rivera brings more than 25 years of experience in the biotech industry to this role and joins AGC Biologics after working for Samsung Biologics for more than eight years.
Before her time at Samsung, she spent nearly a decade with Janssen Pharmaceutical’s research and development division, supporting pilot plant operations and managing outsourcing activities.
“I am delighted to join AGC Biologics at such an exciting time of growth for the company and at such a transformational time for our industry,” said Choi-Rivera.
“The strong track record of biopharmaceutical innovation and technical capabilities at this facility, coupled with world-class talent, puts the Boulder site in position to help deliver important treatments that can truly change the lives of patients for years to come.”
AGC Biologics acquired the Boulder Facility in June 2020, giving the company additional capacity and a significantly larger production scale for mammalian-based projects in the U.S.
The Boulder site houses two 20,000-litre stainless steel cell bioreactors and has more than 20 acres of undeveloped land, creating opportunities for future expansion, including space for up to four more 20,000-litre bioreactors.
-- BERNAMA
No comments:
Post a Comment